(Re)posicionamento estratégico em redes : um estudo de caso

Mestrado em MarketingA liberalização do mercado da energia em Portugal trouxe alterações profundas ao sector, com consequências para as empresas que nele operam. No caso particular do gás natural, a liberalização permitiu a entrada de novas empresas e a realização de investimentos substanciais na expansão das suas redes de distribuição. Sendo o gás natural uma alternativa ao GPL (Gás de Petróleo Liquefeito) as empresas comercializadoras de GPL deparam-se com alterações no seu ambiente. É objectivo deste trabalho analisar, através de um estudo de caso, a forma como uma empresa a operar neste sector, foi construindo e redefinindo a sua estratégia num período tão particular da história do sector. Tendo por base uma visão relacional do sistema industrial, recorre-se a um modelo de actuação estratégica em redes centrado na noção de posição na rede. Este estudo pretende avaliar em que medida, e no quadro da sua teoria de rede, as actuações da empresa focal com vista a alterar a sua posição na rede e desenvolver uma nova posição noutra rede, afectaram as (ou foram afectadas pelas) acções e posições de alguns operadores na(s) rede(s). O presente estudo permite concluir pela robustez do modelo, suportando a noção de que as alterações (ou manutenção) de posição envolvem sempre outras empresas na rede, nomeadamente as suas teorias de rede e as suas posições tanto na rede focal como, eventualmente, noutras redes conectadas. Neste quadro, e como ilustrado neste estudo, a autonomia estratégica de uma empresa na rede pode revelar-se mais aparente do que real.The liberalization of the Portuguese energy market brought profound changes to the national energy sector, with consequences to the companies operating in it. In particular, the liberalization of the natural gas market allowed new companies to enter the market as well as the expansion of gas distribution infrastructures. As natural gas is an alternative to LPG (Liquefied Petroleum Gas), LPG selling companies are faced with significant changes in their environment. The purpose of this study is to analyze, through a case study, the process through which a company operating in the LPG sector developed and redefined its strategy over time, in such a particular period of the sector’s history. Adopting a relational approach to the industrial system, this study uses the network positions and strategic action analytic framework, built on the network theory model. This study intends to evaluate how and to what extent did the focal company’s strategic actions, intended to change its network position and create a new position on another network, influenced, and were influenced by, the actions and positions of other actors on both networks. The results of this study confirm the consistency of the theoretical model, allowing us to conclude that a change in (or maintenance of) a company’s network position depends on the other actors on the network, more specifically on their network theories and positions, both on the focal and in other connected networks. In this context, and as this study shows, a company’s strategic independence can be more apparent than real

Flebite associada a cateter venoso periférico e a administração de medicamentos: análise retrospetiva de incidentes

Background: Phlebitis is a complication associated with peripheral intravenous catheters and an adverse event. Objective: To analyze peripheral intravenous catheter-associated phlebitis incidents associated and drug administration to adult inpatients and their consequences. Methodology: Quantitative, retrospective, descriptive, and cross-sectional study. Non-probabilistic convenience sampling technique was used, with 96 adult patients hospitalized in 2019 selected in the area of medicine at a Hospital Center in Lisbon. The type of phlebitis incident was characterized using the Visual Infusion Phlebitis scale adapted and translated to European Portuguese. Patient harm was categorized according to the International Classification for Patient Safety (ICPS). Results: Of the documented phlebitis incidents, 78% obtained a score 2 on the VIP PT-PT scale. According to the ICPS, 87.5% resulted in mild harm and 12.5% in moderate harm. Antibiotics were the most frequent therapeutic group. Conclusion: Phlebitis has an impact on patient safety. The importance of nursing care is reinforced, with a focus on surveillance and early detection of phlebitis to prevent complications.Enquadramento: A flebite é uma complicação associada à utilização de cateter venoso periférico, classificada como evento adverso. Objetivos: Analisar os incidentes de flebite associada ao cateter venoso periférico e aos medicamentos administrados em doentes adultos internados e as suas consequências. Metodologia: Estudo quantitativo, retrospetivo, descritivo e transversal. Técnica de amostragem não probabilística por conveniência sendo selecionados 96 doentes adultos internados em 2019, na área da medicina de um Centro Hospitalar em Lisboa. O grau de flebite foi avaliado pela escala Visual Infusion Phlebitis Score Português Portugal (VIP PT-PT) traduzida e adaptada para Português Europeu. O dano foi categorizado de acordo com a classificação internacional sobre segurança do doente(CISD). Resultados: Dos incidentes de flebite documentados, 78% classificados com score 2 pela escala VIP PT-PT. Pela CISD, 87,5% resultaram em dano ligeiro e 12,5% em moderado. Os antibióticos foram o grupo terapêutico mais frequente. Conclusão: A flebite tem impacto na segurança do doente. Reforça-se a importância dos cuidados de enfermagem com enfoque na vigilância e deteção precoce de flebite.info:eu-repo/semantics/publishedVersio

Práticas artísticas no ensino básico e secundário

A educação artística passa por circunstâncias paradoxais, que se originam na sua essencialidade plástica: o desenho cada vez é menos praticado no papel e cada vez é mais praticado no ecrã. A experiência plástica do corpo a corpo, da “afinidade” através da convenientia, da aemulatio, da analogia, e das simpatias (Foucault), pode já ser cada vez mais reduzida, ou mesmo residual. Hoje a experiência digital antecede a experiência analógica desde a mais tenra idade, e este é um novo contexto que nos mostra águas desconhecidas. Haverá uma “fraqueza analógica” contemporânea? Como fundar uma experiência quando o digital já quase antecede o analógico, na educação e no desenvolvimento da criança?Como compreender o desconhecido com base no desconhecido? Diga-se, no mínimo, que em Educação Artística, a Matéria-Prima complicou-se. Os 18 artigos aqui presentes dão um contributo vivo para uma reflexão, tanto sobre a sua operacionalização como sobre a sua concetualização, atenta às contradições e paradoxos, disponível para os novos contributos, as novas intervenções.info:eu-repo/semantics/publishedVersio

SARS-CoV-2 introductions and early dynamics of the epidemic in Portugal

Genomic surveillance of SARS-CoV-2 in Portugal was rapidly implemented by the National Institute of Health in the early stages of the COVID-19 epidemic, in collaboration with more than 50 laboratories distributed nationwide. Methods By applying recent phylodynamic models that allow integration of individual-based travel history, we reconstructed and characterized the spatio-temporal dynamics of SARSCoV-2 introductions and early dissemination in Portugal. Results We detected at least 277 independent SARS-CoV-2 introductions, mostly from European countries (namely the United Kingdom, Spain, France, Italy, and Switzerland), which were consistent with the countries with the highest connectivity with Portugal. Although most introductions were estimated to have occurred during early March 2020, it is likely that SARS-CoV-2 was silently circulating in Portugal throughout February, before the first cases were confirmed. Conclusions Here we conclude that the earlier implementation of measures could have minimized the number of introductions and subsequent virus expansion in Portugal. This study lays the foundation for genomic epidemiology of SARS-CoV-2 in Portugal, and highlights the need for systematic and geographically-representative genomic surveillance.We gratefully acknowledge to Sara Hill and Nuno Faria (University of Oxford) and Joshua Quick and Nick Loman (University of Birmingham) for kindly providing us with the initial sets of Artic Network primers for NGS; Rafael Mamede (MRamirez team, IMM, Lisbon) for developing and sharing a bioinformatics script for sequence curation (https://github.com/rfm-targa/BioinfUtils); Philippe Lemey (KU Leuven) for providing guidance on the implementation of the phylodynamic models; Joshua L. Cherry (National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health) for providing guidance with the subsampling strategies; and all authors, originating and submitting laboratories who have contributed genome data on GISAID (https://www.gisaid.org/) on which part of this research is based. The opinions expressed in this article are those of the authors and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States government. This study is co-funded by Fundação para a Ciência e Tecnologia and Agência de Investigação Clínica e Inovação Biomédica (234_596874175) on behalf of the Research 4 COVID-19 call. Some infrastructural resources used in this study come from the GenomePT project (POCI-01-0145-FEDER-022184), supported by COMPETE 2020 - Operational Programme for Competitiveness and Internationalisation (POCI), Lisboa Portugal Regional Operational Programme (Lisboa2020), Algarve Portugal Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), and by Fundação para a Ciência e a Tecnologia (FCT).info:eu-repo/semantics/publishedVersio

Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020

We show the distribution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic clades over time and between countries and outline potential genomic surveillance objectives. We applied three genomic nomenclature systems to all sequence data from the World Health Organization European Region available until 10 July 2020. We highlight the importance of real-time sequencing and data dissemination in a pandemic situation, compare the nomenclatures and lay a foundation for future European genomic surveillance of SARS-CoV-2

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Prostitución: qué modelo jurídico-político para portugal?

A prostituição em Portugal conheceu diversos modelos jurídico-políticos, como a regulamentação, o proibicionismo e o abolicionismo, prevalecendo este último na atualidade. No discurso social e científico encontramos sobretudo duas posições: os defensores da prostituição como trabalho e os que a consideram uma violação dos direitos humanos. Este artigo apresenta a evolução histórico-legal dos modelos de intervenção na prostituição em Portugal, de forma a contextualizarmos e compreendermos a influência dos discursos. Em seguida, expõe as opiniões dos profissionais das instituições, que dirigem respostas a esta população, sobre a atual moldura jurídico-política, com a finalidade de analisar as diferentes perspectivas sobre o trabalho sexual. Baseando-se em pesquisa de natureza qualitativa que contemplou 23 entrevistas, conclui-se que embora não exista uma ideia clara sobre qual modelo adotar, a preocupação com o respeito pelos direitos humanos e o combate ao estigma estão patentes, independentemente do paradigma em questão.Different political-juridical models have framed prostitution in Portugal: regulation, prohibition and abolition, the latter of which is currently prevalent. There are two main standpoints in social and scientific discourse: those who defend prostitution as a valid form of labor and those who consider it a violation of human rights. This article presents the legal and historical evolution of models of interventions concerning prostitution in Portugal, so as to contextualize and understand the influence of discourses. Next, the article exposes the opinion of professionals within institutions that respond to the demands of this population, under the current political-juridical framework, with the objective of analyzing different perspectives on sexual labor. Based on qualitative research which tooks into account 23 interviews, it was concluded that although there is not a clear idea as to which model to adopt, the concern regarding respect for human rights and the combatting stigma is well-established, regardless of the paradigm in question.La prostitution au Portugal a connu divers modèles juridico-politiques, tels que la réglementation, la prohibition et l’abolitionnisme, ce dernier étant celui qui prévaut actuellement. Dans le discours social et scientifique, deux positions dominantes se dessinent: la défense de la prostitution comme travail et l’idée selon laquelle elle constituerait une violation des droits humains. Cet article présentera l’évolution historico-légale des modèles d’intervention dans la prostitution au Portugal, de façon à contextualiser et à comprendre l’influence des différents discours. Nous exposerons ensuite les opinions sur le cadre juridico-politique émises par des professionnels d’institutions prenant en charge cette population spécifique, dans le but d’analyser les différentes perspectives sur le travail sexuel. Sur la base d’une étude qualitative comprenant 23 entretiens, nous avons conclu que même s’il n’existait pas d’idée claire sur le modèle à adopter, le respect des droits humains et la lutte contre la stigmatisation constituaient des préoccupations centrales, et ce indépendamment du paradigme en question.La prostitución en Portugal ha conocido a lo largo del tiempo diversos modelos jurídico-políticos: la reglamentación, el prohibicionismo y el abolicionismo, siendo este último todavía prevaleciente en la actualidad. En el discurso social y científico encontramos sobre todo dos posiciones: los defensores de la prostitución como trabajo y aquellos que la consideran una violación de los derechos humanos. Este artículo presenta la evolución histórico-letal de los modelos de intervención en la prostitución en Portugal, como forma de contextualizar y comprender la influencia de los discursos. Enseguida, expone las opiniones de los profesionales de las instituciones, que dirigen respuestas a esta población, sobre el actual marco jurídico-político, con la finalidad de analizar las diferentes perspectivas sobre el trabajo sexual. Basándose en una investigación cualitativa que contempló 23 entrevistas, la conclusión sugiere que aunque no exista una idea clara sobre que modelo adoptar, la preocupación con el respeto a los derechos humanos y el combate al estigma están patentes, independiente del paradigma en cuestión